Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Context TherapeuticsSTU:6K9 +1.96%36 Market Cap is €49.79 Mil as of Jul. 30, 2026. GuruFocus rates STU:6K9 with a GF Score™ of 36/100. The stock has 1 warning sign investors should review. Among 1,421 Biotechnology companies, Context Therapeutics ranks worse than 60.52% on this metric.
Context Therapeutics's quarterly market cap
increased
from Sep. 2025 (€71.21 Mil) to Dec. 2025 (€88.20 Mil) and
increased
from Dec. 2025 (€88.20 Mil) to Mar. 2026 (€205.81 Mil).
Context Therapeutics's annual market cap
increased
from Dec. 2023 (€16.44 Mil) to Dec. 2024 (€91.50 Mil) but then
declined
from Dec. 2024 (€91.50 Mil) to Dec. 2025 (€88.20 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Context Therapeutics's Enterprise Value for Today is €2.15 Mil.
Context Therapeutics (STU:6K9) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Context Therapeutics Market Cap Related Terms
Context Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Context Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Context Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Context Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Context Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Context Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Context Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Context Therapeutics (STU:6K9) has a Market Cap of €49.79 Mil as of Jul. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Context Therapeutics and its competitors. According to the industry distribution chart, Context Therapeutics ranks #860 out of 1421 companies in the Biotechnology industry, placing it in the top 60.5%.
Is Context Therapeutics' Market Cap too high?
Context Therapeutics' current Market Cap is €49.79 Mil. Based on the distribution chart, Context Therapeutics ranks #860 out of 1421 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Context Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Context Therapeutics' Market Cap compare to INKT and XLO?
According to the Biotechnology industry distribution chart, Context Therapeutics ranks #860 out of 1421 companies for Market Cap. This places Context Therapeutics in the lower half of its industry. The industry median Market Cap is 111.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 111.82, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Context Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 111.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Context Therapeutics's current Market Cap is €49.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Context Therapeutics stock overvalued right now?
Context Therapeutics (STU:6K9) has a current Market Cap of €49.79 Mil. The current Market Cap is €49.79 Mil. Context Therapeutics' overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Context Therapeutics (STU:6K9), the current Market Cap is €49.79 Mil as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
36GF Score
Get the complete analysis for STU:6K9
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6K9 has been successfully added to your 
